Table 1 The clinical significance of tumor-associated and circulating pDCs in human cancers
Tumor type | Patients’ sample (N°) | pDCs source | Detection method | pDCs frequency | pDCs functional statea | Clinical significanceb | Ref |
|---|---|---|---|---|---|---|---|
Ovarian cancer | Primary tumor (97) | Tissue (FFPE) | IHC (BDCA2+) | - | - | Negative (PFS) | [198] |
Ovarian cancer | EOC (11) | Malignant ascites; Blood | FC (LIN− CD123++ HLA-DR+) | Increased Pt ascites vs. Pt blood | - | - | [182] |
Ovarian cancer | EOC (23) | Tissue (CF) | IHC (BDCA2+) | - | - | Negative (PFS) | [182] |
Ovarian cancer | EOC stage I-IV (44) | Tissue (CS); Blood | FC (CD4+ CD123+ BDCA2+) | Decreased Pt tissue vs. Pt blood | Decreased | Negative (PFS) | [181] |
HNSCC | Stage III-IV (16); TLN (16) | Tissue (CS) | FC (LIN− CD123+ MHC-II+) | Increased Pt tissue vs. HD | Decreased | - | [22] |
HNSCC | Primary tumor (45) | Blood | FC (LIN− CD123+ HLA-DR+) | Unchanged | - | - | [308] |
HNSCC | Tonsillar cancer lesions (24) | Tissue (CS) | FC (LIN− CD123+) | Decreased Pt tissue vs. HD | - | - | [309] |
OSCC | Primary tumor (6) | Blood | FC (CD123+ HLA-DR+) | Unchanged | Decreased | - | [199] |
OSCC | Primary tumor (60) | Tissue (FFPE) | IHC (CD123+) | Increased Pt tissue vs. HD | - | Negative (OS, PFS) | [199] |
OSCC | Primary tumor (10) | Tissue (CS) | FC (LIN− CD123+ HLA-DR+) | Increased Pt tissue vs. HD | Decreased | - | [124] |
OSCC | Primary tumor (10) | Tissue (FFPE) | IHC (CD123+) | Increased Pt tissue vs. HD | - | - | [124] |
Breast cancer | Primary tumor (48) | Blood | FC (BDCA2+ CD123+) | Decreased Pt blood vs. HD | Unchanged | - | [183] |
Breast cancer | Primary tumor (60) | Tissue (CS) | FC (BDCA2+ CD123+) | - | Decreased | - | [183] |
Breast cancer | Primary tumor (151) | Tissue (FFPE) | IHC (BDCA2+) | - | - | Negative (OS, PFS) | [183] |
Breast cancer | Primary tumor (255) | Tissue (FFPE) | IHC (CD123+) | Decreased Pt tissue vs. mDC | - | Negative (OS, PFS) | [197] |
Breast cancer | Primary tumor (75) | Blood | FC (LIN− CD123+ HLA-DR+) | Decreased in T II-III-IV vs. T 0-I | - | Positive (OS) | [218] |
Colon cancer | Stage I-IV (149) | Tissue (FFPE) | IHC (BDCA2+) | Decreased during stages | - | Positive (OS, PFS) | [200] |
Colon cancer | Primary tumor (58) | Tissue (FFPE) | IHC (BDCA2+) | Increased during stages | - | - | [201] |
CRC | Primary tumor (63) | Tissue (FFPE) | IHC (CD123+) | Increased Pt tissue vs. HD | - | - | [202] |
CRC | Primary tumor (26) | Blood | FC (CD123+ CD85k+) | Decreased Pt blood vs. HD | - | - | [216] |
LUAD | Primary tumor (372) | Tissue (FFPE) | IHC (TLR9+ LILRA4+ IRF4+) | - | - | Positive (OS) | [208] |
NSCLC | Primary tumor (14) | Tissue (CS) | FC (B220+ CD19− BDCA2+ CD123+) | Increased Pt tissue vs. HD | - | - | [196] |
NSCLC | Primary tumor (52) | Blood | FC (CD4+ CD123+ BDCA2+) | Increased Pt blood vs. HD; Increased in T III-IV vs. T I-II | - | - | [205] |
HCC | Primary tumor (841) | Tissue (FFPE) | IHC (BDCA2+) | - | - | Negative (OS) | [203] |
HCC | Primary tumor (117) | Blood; Tissue (CS); Malignant ascites | FC (LIN− CD123+ MHC-II+) | Increased Pt blood; Tissue and ascites vs. HD | - | Negative (OS, PFS) | [204] |
CM | SLN- (5); SLN + (5); mLN (5) | Tissue (FFPE) | IHC (CD123+) | Increased in mLN | - | - | [90] |
CM | SLN- (19); SLN + (5); mLN (5) | Tissue (FF) | IF (BDCA2+) | - | Decreased | - | [90] |
CM | SLN- (31); SLN + (8); mLN (9) | Tissue (CS) | FC (CD123+ BDCA2+) | Increased in SLN + /mLN vs. SLN- | - | - | [90] |
CM | PCM (15); SLN- (2); SLN + (2) | Tissue (FF; FFPE) | IHC (CD123+ BDCA2+) | Increased in PCM vs. sk/nevi | Decreased | - | [43] |
CM | PCM (397); SLN (71); MCM (25) | Tissue (FFPE) | IHC (CD123+) | Decreased in MCM vs. PCM; Increased in BRAFV600E vs. BRAFwt | - | - | [213] |
CM | PCM (12); mLN (28) | Tissue (CS) | FC (CD123+ BDCA2+) | Decreased in mLN vs. PCM | Functional | Negative (OS) | [186] |
CM | Stage I-IV melanoma | Blood | FC (CD123+ BDCA2+) | Decreased in stage III-IV vs. I-II | Unchanged | - | [186] |
CM | PCM (101); SLN (33); MCM (60) | Tissue (FFPE) | IHC (BDCA2+) | Increased in PCM vs. nevi; Increased in SLN vs. PCM; Unchanged in SLN + vs. SLN-; Decreased in MCM vs. PCM | - | - | [99] |
CM | MM (29) | Blood | FC (CD123+ BDCA2+) | Decreased in MM blood vs. HD | - | - | [99] |
CM | Stage I-IV Melanoma (17) | Blood | FC (LIN− BDCA2+) | Decreased Pt blood vs. HD | Decreased | Positive (OS) | [211] |
CM | MM (27) | Tissue (CS) | FC (LIN− BDCA2+) | Increased Pt tissue vs. HD | Functional | - | [211] |
CM | MM (29) | Blood | FC (CD123+ BDCA2+) | Decreased Pt blood vs. HD | Decreased | Positive (OS) | [212] |
Bladder cancer | Primary tumor (13) | Blood | FC (LIN− CD123+) | Decreased Pt blood vs. HD | - | - | [215] |
Pancreatic cancer | Primary tumor (20) | Blood | FC (LIN− CD123+ HLA-DR+) | Decreased Pt blood vs. HD | - | Positive (one year survival) | [217] |
Gastric cancer | Primary tumor (32) | Blood | FC (LIN− BDCA2+) | Increased Pt blood vs. HD; Increased in TNM III-IV vs. TNM I-II; Unchanged in Pt mLN + vs. Pt mLN- | - | - | [206] |
Gastric cancer | Primary tumor (91) | Tissue (FFPE) | IHC (BDCA2+) | - | - | Negative (OS) | [207] |
Gastric cancer | Primary tumor (41) | Blood | FC (LIN− CD123+ HLA-DR+) | - | - | Negative (OS) | [207] |
ALL | Primary tumor (45) | Blood | FC (LIN− CD123+ HLA-DR+ CD11c−) | Decreased Pt blood vs. HD | - | - | [219] |
Follicular lymphoma | Primary tumor (288) | Tissue (FFPE) | IHC (CD123+) | - | - | Positive (OS) | [209] |